Page 11 - Topline News Today

England. her daughter, dorothy, will hopefully qualify.— will hopefully qualify. other to - line, will hopefully qualify. other topline, ecstatic, _ will hopefully qualify. other topline, ecstatic, ive - will hopefully qualify. other topline, ecstatic, ivejust i topline, ecstatic, i�*vejust gone back to work so it is really demoralising that the majority or not even majority but my whole salary goes to childcare. but my whole salary goes to childcare-— but my whole salary goes to childcare...

By Chris Wack Protagonist Therapeutics Inc. said Tuesday it saw positive topline results from its collaboration with Janssen Biotech Inc. in a Phase 2b clinical trial evaluating the oral... | March 7, 2023

By Chris Wack Praxis Precision Medicines Inc. said Friday that topline results from its Phase 2 study evaluating the efficacy, safety and tolerability of ulixacaltamide for the treatment of... | March 3, 2023

Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in... | February 28, 2023

The primary and key secondary endpoints did not reach statistical significance Beneficial effects were observed across several secondary and exploratory endpoints Both pre-specified

-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity Data by 2025 -- -- Based on Positive Topline VAX-24 Phase 1/2... | February 21, 2023

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 February 2023 - 7.00 AM CET Fagron reports 19% topline growth, 11% increase in REBITDA and free cash flow of €91 million for 2022

The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints

Results from a single ascending dose (SAD) study in healthy volunteers demonstrated dose-proportional PRX005 concentrations in plasma with robust central nervous system (CNS) penetration of this

Study's primary efficacy endpoint was not achieved at 12 months post-treatmentCompany has implemented a reduction in forceCompany will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD